Pull to refresh
Logo
China approves first AI-assisted Class 1 innovative drug Mprosevir

China approves first AI-assisted Class 1 innovative drug Mprosevir

New Capabilities

COVID-19 treatment went from candidate discovery to conditional approval in 3.5 years, about a third of the traditional timeline

2 days ago: NMPA grants conditional approval to Mprosevir

Overview

Updated 1 hour ago

China's drug regulator granted conditional approval to Mprosevir, a COVID-19 treatment, on September 2. It is the country's first 'Class 1' innovative drug developed with AI assistance—the highest classification in China's drug registration system, reserved for drugs never marketed domestically or abroad.

Mprosevir took 3.5 years from candidate discovery to clinical trial completion, about a third of the traditional decade-long pipeline. Researchers screened 49 billion compounds in a DNA-encoded library (DEL), with AI narrowing more than 100 candidates to nine molecules within days. It is the first small-molecule drug approved worldwide using DEL technology, a concept proposed 34 years ago.

Why it matters

AI-assisted drug development can compress a decade-long pipeline into years, changing how quickly new medicines reach patients.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

3.5 years
Development time from discovery to trial completion
Traditional small-molecule drug development takes 10+ years on average.
49 billion
Compounds screened in the DEL library
DNA-encoded library screening combined with AI virtual filtering identified candidates in days.
9
Lead candidates after AI screening
AI narrowed over 100 initial candidates; 6 of the 9 showed strong activity in testing.
34 years
Time from DEL concept to first approved drug
The DEL technology concept was first proposed in 1992.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict. Log in Sign Up
Predict 3 ways this could play out. Back the one you believe — contrarian picks score more when a scenario has a resolution date. Log in to play

People Involved

Organizations Involved

Timeline

January 1992 September 2026

5 events Latest: 2 days ago
Tap a bar to jump to that date
  1. NMPA grants conditional approval to Mprosevir

    Latest Regulatory Approval

    China approves first AI-assisted Class 1 innovative drug for mild-to-moderate COVID-19 in adults.

  2. Two-year AI-guided optimization completed

    Development

    Team improves potency, pharmacology, and toxicity. Progresses from cell assays through mouse studies toward clinical trials.

  3. AI narrows candidates; WLU6937 selected

    Discovery

    AI filters 100+ candidates to nine in days; six show strong activity. WLU6937 chosen as lead.

  4. Westlake team begins DEL screening campaign

    Discovery

    Researchers screen 49 billion compounds in a DEL library targeting the 3CLpro coronavirus protease.

  5. DNA-encoded library concept proposed

    Scientific Context

    Sydney Brenner and Richard Lerner introduce the DEL concept, enabling compound screening at massive scale.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

January 2020 - December 2021

COVID-19 mRNA vaccines (2020-2021)

Operation Warp Speed and the new mRNA platform compressed vaccine development from the typical 10-15 years to under a year. Pfizer-BioNTech and Moderna moved from sequence to emergency authorization in about 11 months, a process that normally takes a decade.

Then

Billions of doses delivered worldwide within 18 months of the pandemic's start.

Now

Demonstrated that regulatory flexibility plus platform innovation can compress biological product timelines dramatically, reshaping vaccine development norms.

Why this matters now

The same dynamic is at work with Mprosevir: a new discovery platform (DEL plus AI) combined with regulatory adaptation compresses a decade-long process into years.

November 2020 - July 2021

AlphaFold protein structure breakthrough (2020-2021)

DeepMind's AlphaFold solved the 50-year protein folding problem, predicting protein structures with atomic accuracy. In 2021, AlphaFold released structures for nearly all of the 200 million proteins cataloged in science—work that would have taken researchers centuries.

Then

Structural biologists gained instant access to predictions for proteins they had spent years trying to crystallize.

Now

Established that AI can outperform traditional experimental methods in biological discovery, fueling investment in AI-driven drug development.

Why this matters now

Mprosevir builds directly on this precedent: AI applied to biological problems changes what's possible, and what was a research tool in 2021 is now producing approved drugs.

1970s-present

Drug development's 'three tens' rule

The pharmaceutical industry's long-standing benchmark: 10 years of development, $1 billion in investment, and less than 10% probability of success for a new drug. This baseline has held for decades despite advances in chemistry, genomics, and screening technology.

Then

High development costs and failure rates have kept drug prices high and limited innovation to well-capitalized firms.

Now

The rule set expectations for how long patients wait for new treatments and how much risk investors accept.

Why this matters now

Mprosevir challenges the baseline directly—3.5 years versus 10, with AI handling screening and optimization that historically consumed years of medicinal chemistry effort.

Sources

(7)